Abstract

BackgroundDespite the potential to produce antibodies that can neutralize different virus (heterotypic neutralization), there is no knowledge of why vaccination against influenza induces protection predominantly against the utilized viral strains (homotypic response). Identification of structural patterns of the B cell repertoire associated to heterotypic neutralization may contribute to identify relevant epitopes for a universal vaccine against influenza.MethodsBlood samples were collected from volunteers immunized with 2008/2009 trivalent inactivated vaccine (TIV), pandemic H1N1 (pdmH1N1) monovalent inactivated vaccine (MIV) and the 2014/2015 TIV. Neutralization was assessed by hemagglutination and microneutralization test. IgG VH amplicons derived from peripheral blood RNA from pre-immune and 7 days post vaccination were subjected to 454-Roche sequencing. Full reconstruction of the sampled repertoires was done with ImmunediveRsity.ResultsThe TIV induced a predominantly homotypic neutralizing serologic response, while the 09 MIV induced a heterotypic neutralizing seroconversion in 17 % of the individuals. Both the 08/09 and the 14/15 TIV were associated with a reduction in clonotypic diversity, whereas 09 MIV was the opposite. Moreover, TIV and MIV induced distinctive patterns of IGHV segment use that are consistent with B cell selection by conserved antigenic determinants shared by the pre-pandemic and the pandemic strains. However, low somatic hypermutation rates in IgG after 09 MIV immunization, but not after 08/09 and 14/15 TIV immunization were observed. Furthermore, no evidence of the original antigenic sin was found in the same individuals after vaccination with the three vaccines.ConclusionsImmunization with a new influenza virus strain (2009 pdmH1N1) induced unique effects in the peripheral B cell repertoire clonal structure, a stereotyped response involving distinctive IGHV segment use and low somatic hypermutation levels. These parameters were contrastingly different to those observed in response to pre-pandemic and post-pandemic vaccination, and may be the result of clonal selection of common antigenic determinants, as well as germinal center-independent responses that wane as the pandemic strain becomes seasonal. Our findings may contribute in the understanding of the structural and cellular basis required to develop a universal influenza vaccine.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-015-0239-y) contains supplementary material, which is available to authorized users.

Highlights

  • Despite the potential to produce antibodies that can neutralize different virus, there is no knowledge of why vaccination against influenza induces protection predominantly against the utilized viral strains

  • Each heavy chainencoding plasmid was co-transfected with each of the Vaccination with the 08/09 trivalent inactivated vaccine (TIV) does not induce seroconversion against 2009 pandemic H1N1 (pdmH1N1) During the onset of the pandemic (May, 2009), six individuals were vaccinated with the 08/09 TIV

  • The preimmune serum of three (50 %) and two (33.3 %) individuals showed positive hemagglutination inhibition assay (HIA) for 2008 A(H1N1) and 2008 A(H3N2), respectively, which is indicative of pre-exposure to seasonal viruses and is expected among the general population

Read more

Summary

Introduction

Despite the potential to produce antibodies that can neutralize different virus (heterotypic neutralization), there is no knowledge of why vaccination against influenza induces protection predominantly against the utilized viral strains (homotypic response). HA is trimeric, and each monomer contains a globular domain with a high mutation frequency and a stem with a more conserved structure [3] Both natural infection and vaccination induce the production of neutralizing antibodies mainly directed against the globular domain, known as homotypic neutralizing antibodies, which are incapable of neutralizing other virus subtypes or certain drift variants of the original subtype. As for why heterotypic neutralizing antibodies do not prevail over homotypic neutralizing antibodies, and why they are not produced in all individuals in relevant amounts to provide protection remain open questions The answer to these questions would open up the possibility of developing a universal vaccine that may prevent a significant number of virus subtypes, including new variants with pandemic potential [11,12,13,14]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.